**Artemisia annua: Trials are needed for COVID-19**

[Faiz Ul Haq](https://pubmed.ncbi.nlm.nih.gov/?term=Haq+FU&cauthor_id=32424845) [1](https://pubmed.ncbi.nlm.nih.gov/32424845/#affiliation-1)  [2](https://pubmed.ncbi.nlm.nih.gov/32424845/#affiliation-2) , [Muhammad Roman](https://pubmed.ncbi.nlm.nih.gov/?term=Roman+M&cauthor_id=32424845) [2](https://pubmed.ncbi.nlm.nih.gov/32424845/#affiliation-2) , [Kashif Ahmad](https://pubmed.ncbi.nlm.nih.gov/?term=Ahmad+K&cauthor_id=32424845) [1](https://pubmed.ncbi.nlm.nih.gov/32424845/#affiliation-1)  [3](https://pubmed.ncbi.nlm.nih.gov/32424845/#affiliation-3) , [Saeed Ur Rahman](https://pubmed.ncbi.nlm.nih.gov/?term=Rahman+SU&cauthor_id=32424845) [4](https://pubmed.ncbi.nlm.nih.gov/32424845/#affiliation-4) , [Syed Murtaza Ali Shah](https://pubmed.ncbi.nlm.nih.gov/?term=Shah+SMA&cauthor_id=32424845) [2](https://pubmed.ncbi.nlm.nih.gov/32424845/#affiliation-2) , [Naveed Suleman](https://pubmed.ncbi.nlm.nih.gov/?term=Suleman+N&cauthor_id=32424845) [5](https://pubmed.ncbi.nlm.nih.gov/32424845/#affiliation-5) , [Sami Ullah](https://pubmed.ncbi.nlm.nih.gov/?term=Ullah+S&cauthor_id=32424845) [6](https://pubmed.ncbi.nlm.nih.gov/32424845/#affiliation-6) , [Iftekhar Ahmad](https://pubmed.ncbi.nlm.nih.gov/?term=Ahmad+I&cauthor_id=32424845) [1](https://pubmed.ncbi.nlm.nih.gov/32424845/#affiliation-1) , [Wajahat Ullah](https://pubmed.ncbi.nlm.nih.gov/?term=Ullah+W&cauthor_id=32424845) [1](https://pubmed.ncbi.nlm.nih.gov/32424845/#affiliation-1)

**Abstract**

In December 2019, a number of pneumonia cases associated with 2019 novel coronavirus occurred in Wuhan, China. Later taxonomist name the virus SARS‐CoV‐2 and disease called COVID‐19. No approved vaccine or treatment are available for this virus. Current technical guide is related to address therapeutic option for SARS‐CoV‐2. COVID‐19 is great challenge for scientist across the globe. Bioactive compound present in *Artemisia annua* against, hepatitis B virus, bovine viral diarrhea virus, and Epstein–Barr virus. *A. annua* have shown significant activity against SARS coronavirus that occur in 2002*.* This agent is cheap and easily available and will be of great value if they have efficacy against SARS‐CoV‐2. Scientific attention is needed toward this agent to address for the treatment of COVID‐19.